An adult stem cell center established by the Kansas Legislature in 2013 is almost ready for its first clinical trial.
Buddhadeb Dawn, executive director of the Midwest Stem Cell Therapy Center, told legislators Tuesday that the trial will focus on treating graft-versus-host disease and will begin after final approvals from the U.S. Food and Drug Administration.
“Our goal was to do this (trial) in January, but we got delayed because of different things,” Dawn said during a hearing of the House Health and Human Services Committee. “So we are now hoping to start it perhaps in summer.”
Based at the University of Kansas Medical Center in Kansas City, the stem cell center has analyzed trials done elsewhere and hosted a clinical trial sponsored by a biotech company that uses modified stem cells from bone marrow to treat stroke.